
Claims

1. A PARP1 inhibitor compound for use in medicine, which compound comprises a structure of:



wherein:

R^1 is selected from H, a C1 to C6 alkyl, aminoalkyl, alkoxy or haloalkyl group; a C3 to C6 cycloalkyl group; a halogen group; and $C(R^{22})(R^{23})_2$;

with the proviso that at least one of R^1 and R^2 is not H, R^2 is absent or selected from H, a C1 to C6 alkyl, aminoalkyl, alkoxy or haloalkyl group; a C3 to C6 cycloalkyl group; a halogen group; and $-C(R^{22})(R^{23})_2$;


R^{22} is selected from H, a C1 to C6 alkyl, cycloalkyl, alkoxy, or haloalkyl group; and a halogen group; and


each R^{23} is independently selected from H, a C1 to C6 alkyl, aminoalkyl, alkoxy or haloalkyl group, and a halogen group;

R^3 is absent or selected from H, a halogen, a C1 to C3 alkyl group, a C1 to C3 fluoroalkyl group, a C1 to C3 alcohol group, and a C1 to C3 aminoalkyl group;


Z^1 and Z^2 are each independently selected from C and N; and

L is a group having a structure selected from:





and



wherein:

X^1 is C or N;

each X^2 is independently selected from C and O;

R^{5A2} is absent when the corresponding X^2 is O;

n is 1, 2, or 3;

m is 0, 1, 2, or 3;

the lines forming rings A each independently represent single or double bonds such that ring A is saturated, unsaturated, or aromatic;

wherein:

i) exactly two groups selected from the R^{5A1}, R^{5A2}, and R^{5A3} groups together represent a C1 to C3 alkyl group bridging ring A or a phenyl group fused to ring A, and each other group of the R^{5A1}, R^{5A2}, and R^{5A3} groups is independently absent, H, or an oxo group; or

ii) each R^{5A1}, R^{5A2}, and R^{5A3} is independently H or absent;

each X^C is independently selected from C and N;

when an X^C is N, the corresponding R^{5CO} or R^{5CM} group is absent; and


when an X^C is C, the corresponding R^{5CO} or R^{5CM} group is H or an organic group selected from a halo group; -CN; a C1 or C2 alkyl group; and a C1 or C2 haloalkyl group;

Qb is a bond or $-CH_2-$;

Qc is selected from $-CH_2-$; -O-; and $-NR^8-$, R^8 being H or a C1 to C3 alkyl group; and

R^6:

i) has a structure of



wherein R^{51} is selected from:


a C1 to C6 alkyl group, optionally a C3 to C6 cycloalkyl group, a C1 to C3 alkyl group, or a C1 to C3 deuterated alkyl group;

a C1 to C3 haloalkyl group; and

a 4-, 5-, 6-, or 7-membered saturated heterocyclic group;

or

ii) has a structure of:



wherein:

each X^6 is independently selected from C, N, and O;




R^{61} is absent or H;

each R^{62} is independently absent or selected from H; a halo group; an oxo group; a C1 to C3 alkyl group; a C1 to C3 haloalkyl group; and $-NHR^{63}$, R^{63} being H or a C1 to C3 alkyl group;

or

iii) is selected from -H, -F, -Cl, and -CN.


2. The PARP1 inhibitor compound for use according to claim 1, wherein the compound has a structure selected from:







3. The PARP1 inhibitor compound for use according to claim 1 or claim 2, wherein R^2 is absent or H;


optionally wherein R^2 is H.


4. The PARP1 inhibitor compound for use according to any preceding claim, having a structure selected from:



E1



E2



E3



E4



E5



E6



E7



E8



E9



E10



E11



E12


E13



E14


E15



E16




E17




E18




E19




E20




E21




E22




E23




E24



E25




E26



E27

optionally wherein the PARP1 inhibitor compound has a structure selected from E1 to E10.

5. The PARP1 inhibitor compound for use according to any preceding claim, wherein R^1 is selected from a halogen group; a C1 to C4 alkyl group; and a C1 to C4 haloalkyl group;

optionally wherein R^1 is selected from $-CH_2CH_3$, $-CF_3$, , CH_2CH_2F, Cl, and CH_2CF_3.

6. The PARP1 inhibitor compound for use according to any of claims 1 to 4, wherein R^1 is selected from H, C1 to C3 alkyl, C1 to C3 alkoxy, and C1 to C3 haloalkyl;

optionally wherein R^1 is an ethyl group.

7. The PARP1 inhibitor compound for use according to claim 6, wherein:

Z^1 and Z^2 are each C; and

R^2 and R^3 are each independently selected from H, a halogen, C1 to C3 alkyl, and C1 to C3 haloalkyl;

optionally wherein R^2 and R^3 are each H.

8. The PARP1 inhibitor compound for use according to any preceding claim, wherein ring A is a non-aromatic ring;

optionally wherein ring A is 5-membered or 6-membered.

9. The PARP1 inhibitor compound for use according to claim 8, wherein ring A is selected from:




A1




A28

optionally wherein Qb is -CH_2-.


10. The PARP1 inhibitor compound for use according to claim 8, wherein ring A has a structure selected from:




A2




A3




A4




A5




A6




A7




A8




A9




A10




A11




A12




A13




A14




A15




A16




A17



A18




A24




A25




A28




A29




A30




A31




A32




A33




A34




A35




A36




A37




A39




A40




A41




A42




A43




A44




A45




A46




A47




A48




A49




A50




A51



A52



A53



A54

optionally wherein ring A has a structure selected from A2, A3, A4, A5, A6, A7, A8, and A9;

further optionally wherein ring A has a structure of A9.

11. The PARP1 inhibitor compound for use according to any of claims 1 to 8, wherein:

m is 1 or 2;

n is 1 or 2; and

each X^2 is C.

12. The PARP1 inhibitor compound for use according to any preceding claim, wherein Qb is a bond.


13. The PARP1 inhibitor compound for use according to any preceding claim, wherein ring C is:

i) a phenyl group;

ii) a pyridine group; or

iii) a diazine group.

14. The PARP1 inhibitor compound for use according to claim 13, wherein ring C has a structure of:




wherein:

R^{5C2o} is selected from H and a halogen; and


i) X^{2CM} is C and R^{5C2M} is H; or

ii) X^{2CM} is N and $R5^{C2M}$ is absent.


15. The PARP1 inhibitor compound for use according to any preceding claim, wherein ring C has a structure selected from:




C1




C2




C3




C4




C5




C6




C7




C8




C9




C10




C11




C12





C13





C15











































optionally wherein ring C has a structure selected from C1 to C13 or C15.


16. The PARP1 inhibitor compound for use according to any preceding claim, wherein R^6 is selected from:




17. The PARP1 inhibitor compound for use according to any preceding claim, wherein ring C has a structure selected from:




T1




T2




T3




T4




T5




T6




T7




T8




T9




T10




T11




T12




T13




T14




T15




T16




T17




T18




T19




T20




T21



T22




T23




T24




T25




T26




T27




T28



T29




T31




T32




T34




T35




T36




T37




T38




T39




T40




T41




T42




T43




T44




T45




T46




T47




T48



T49




T50



T51

18. The PARP1 inhibitor compound for use according to any preceding claim, having a structure of:



wherein:

Z^1 and Z^2 are each independently selected from C and N;

when Z^1 is N:

R^2 is absent;

when Z^1 is C:

R^2 is H;

when Z^2 is N:

R^3 is absent;

when Z^2 is C:

R^3 is H;


each X^C is independently selected from C and N; and

when an X^C is N, the corresponding R^{5CO} or R^{5CM} group is absent; and


when an X^C is C, the corresponding R^{5CO} or R^{5CM} group is H or an organic group selected from a halo group, -CN, a C1 or C2 alkyl group, and a C1 or C2 haloalkyl group;

two R^{5A} groups together represent a -CH_2- group, and each other R^{5A} group is H; or each R^{5A} group is H.


19. The PARP1 inhibitor compound for use according to any of claims 1 to 7, wherein group L is selected from:




L1




L2




L3




L4




L5




L6




L7




L8




L9




L10




L11




L12




L13




L14




L15




L16




L17




L18




L19




L20




L21




L22




L23




L24




L25




L26




L27




L28




L29




L30




L31




L33




L34




L35




L36




L37




L38




L39




L40




L41




L42




L43




L44




L45




L46




L47




L48




L49




L50




L51




L52




L53




L54




L55




L56




L57




L58




L59




L60




L61




L62




L63




L64




L65




L66




L67




L70




L71




L72




L73




L74




L75




L76




L77




L78




L79




L80




L81




L82




L83




L84




L85




L86




L87




L88




L1cis




L2cis




L4cis




L6cis




L6trans




L7cis



L7trans




L8cis




L8trans

optionally wherein group L is selected from L1, L1cis, L2, L2cis, L3, L4, L4cis, L5, L6, L6cis, L6trans, L7, L7cis, L7trans, L8, L8cis, and L8trans.


20. The PARP1 inhibitor compound for use according to claim 1, wherein the compound has a structure selected from:




1*cis*




2*cis*




3




4cis




5




6cis




6trans




7cis




7trans




8cis




8trans




9cis




9trans




10




11cis




11trans




12cis




12trans




13cis




13trans




14cis




14trans




15cis




15trans




16




17cis




17trans




18cis




18trans




19cis




19trans




20cis




20trans




21cis




21trans




22cis




22trans




23cis




23trans




24cis




24trans




25cis




25trans




26




27cis




27trans




28cis




28trans




29cis




29trans




30cis




30trans




31cis




31trans




32cis




32trans




33cis




33trans




34




35cis




35trans




36cis




36trans




37cis




37trans




38cis




38trans




39cis




39trans




40cis




40trans




41cis




41trans




42cis




42trans




43cis




43trans




44cis




44trans




45cis




45trans




46cis




46trans




47cis




47trans




48cis




48trans




49cis




49trans




50




51cis




51trans




52cis




52trans




53cis




53trans




54cis




54trans




55cis




55trans




56cis




56trans




57cis




57trans




58cis




58trans




59cis




59trans




60




61




62




63cis




63trans




64




65




66cis




66trans




67cis




67trans




68




69cis




69trans




70




71cis




71trans




72




73cis




73trans




74cis




74trans




75cis




75trans




77cis




77trans




79cis




79trans




80




81cis




81trans




82




83




84




85




86




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106




107




108




109




110




111




112




113




114




115




116




117




118




119



120



121



122

21. Use of the PARP1 inhibitor compound for use according to any preceding claim in the manufacture of a medicament for use in treating a cancer.

22. The use according to claim 21, wherein the PARP1 inhibitor compound is to be administered in conjunction with a further agent for treating cancer.

23. A pharmaceutical composition comprising a PARP1 inhibitor compound for use according to any of claims 1 to 20, and a pharmaceutically acceptable additive and/or excipient.


24. A pharmaceutical kit for treating a cancer, which pharmaceutical kit comprises:

a) a PARP1 inhibitor compound for use according to any of claims 1 to 20; and


b) a further agent for treating cancer;

wherein the compound and the further agent are suitable to be administered simultaneously, sequentially or separately.


25. A compound selected from:




1*cis*




2*cis*




3




4*cis*




5




6*cis*




6*trans*




7*cis*




7*trans*




8*cis*




8*trans*




9cis




9trans




10




11cis




11trans




12cis




12trans




13cis




13trans




14cis




14trans




15cis




15trans




16




17cis




17trans




18cis




18trans




19cis




19trans




20cis




20trans




21cis




21trans




22cis




22trans




23cis




23trans




24cis




24trans




25cis




25trans




26




27cis




27trans




28cis




28trans




29cis




29trans




30cis




30trans




31cis




31trans




32cis




32trans




33cis




33trans




34




35cis




35trans




36cis




36trans




37cis




37trans




38cis




38trans




39cis




39trans




40cis




40trans




41cis




41trans




42cis




42trans




43cis




43trans




44cis




44trans




45cis




45trans




46cis




46trans




47cis




47trans




48cis




48trans




49cis




49trans




50




51cis




51trans




52cis




52trans




53cis




53trans




54cis




54trans




55cis




55trans




56cis




56trans




57cis




57trans




58cis




58trans




59cis




59trans




60




61




62




63cis




63trans




64




65




66cis




66trans




67cis




67trans




68




69cis




69trans




70




71cis




71trans




72




73cis




73trans




74cis




74trans




75cis




75trans




76




77cis




77trans




78cis




78trans




79cis




79trans




80




81cis




81trans




82




83




84




85




86




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102




103




104




105




106




107




108




109




110




111




112




113




114




115




116




117




118




119



120



121



122